Physician profile
Kayd Pulsipher
NPI 1982354080
$9,478.01
in general payments reported to CMS, 2019-2025
22 companies · $3,961 in 2025
The $3,961 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.80 · 2023: $1,193 · 2024: $4,274 · 2025: $3,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,992 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,992.23 |
| Education | $434.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,050.03 | 2023-2025 | |
| Ucb, INC. | $1,195.84 | 2023-2025 | Bimzelx |
| Janssen Biotech, INC. | $1,040.33 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $863.19 | 2023-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $632.92 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $460.36 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $388.64 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $388.04 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $369.41 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $333.12 | 2022-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $320.31 | 2024-2025 | |
| Dermavant Sciences, INC. | $247.80 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $204.05 | 2025 | Cabtreo |
| Blueprint Medicines Corporation | $191.46 | 2025 | Ayvakit |
| Incyte Corporation | $185.41 | 2023-2024 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $172.90 | 2025 | Adbry |
| Convatec INC. | $137.19 | 2024 | |
| Galderma Laboratories, L.P. | $135.11 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $75.37 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.88 | 2023-2024 | Spevigo |
| Biofrontera INC. | $22.25 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $19.40 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayd Pulsipher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.